Tafinlar

Active Ingredient(s): Dabrafenib Mesylate
FDA Approved: * May 29, 2013
Pharm Company: * GLAXOSMITHKLINE
Category: Cancer

Dabrafenib, sold under the brand name Tafinlar & Rafinlar[1] ( both by Novartis) among others, is a medication for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF (V600)-mutated metastatic melanoma.[... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Tafinlar 75 mg Oral Capsule
NDC: 0078-0681
Labeler:
Novartis Pharmaceuticals Corporation
Tafinlar 50 mg Oral Capsule
NDC: 0078-0682
Labeler:
Novartis Pharmaceuticals Corporation
Tafinlar 50 mg Oral Capsule
NDC: 0173-0846
Labeler:
Glaxosmithkline LLC
Tafinlar 75 mg Oral Capsule
NDC: 0173-0847
Labeler:
Glaxosmithkline LLC
Dabrafenib Mesylate
NDC: 53873-023
Labeler:
Glaxosmithkline Inc
Dabrafenib Mesylate
NDC: 53873-024
Labeler:
Glaxosmithkline Inc